<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Mon, 07 Sep 2026 17:50:33 -0400--><rss version="2.0">
    <channel>
        <title>Can-Fite BioPharma Ltd. (CANF) Press Releases</title>
        <link>https://ir.canfite.com/news-events/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/canfite/files/theme/images/logo-sm.png</url>
                <title>Can-Fite BioPharma Ltd. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1125/can-fite-announces-exercise-of-warrants-for-approximately</link>
                <pubDate>Wed, 02 Sep 26 09:02:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1125/can-fite-announces-exercise-of-warrants-for-approximately</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1124/can-fite-reports-longer-than-anticipated-overall-survival</link>
                <pubDate>Wed, 02 Sep 26 07:00:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1124/can-fite-reports-longer-than-anticipated-overall-survival</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1123/can-fite-namodenoson-enhances-the-anti-cancer-effect-of</link>
                <pubDate>Mon, 17 Aug 26 07:00:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1123/can-fite-namodenoson-enhances-the-anti-cancer-effect-of</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1122/can-fite-highlights-advanced-fda-and-ema-regulatory-status</link>
                <pubDate>Wed, 12 Aug 26 07:00:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1122/can-fite-highlights-advanced-fda-and-ema-regulatory-status</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1121/can-fite-launches-first-clinical-program-for-piclidenoson</link>
                <pubDate>Mon, 03 Aug 26 07:00:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1121/can-fite-launches-first-clinical-program-for-piclidenoson</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1120/can-fite-positive-phase-2a-pancreatic-cancer-study-data</link>
                <pubDate>Mon, 20 Jul 26 07:00:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1120/can-fite-positive-phase-2a-pancreatic-cancer-study-data</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1119/can-fite-secures-australian-patent-allowance-supporting</link>
                <pubDate>Tue, 14 Jul 26 07:00:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1119/can-fite-secures-australian-patent-allowance-supporting</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1118/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone</link>
                <pubDate>Mon, 06 Jul 26 07:00:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1118/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1117/can-fite-phase-2a-pancreatic-cancer-study-with-namodenoson</link>
                <pubDate>Wed, 01 Jul 26 07:00:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1117/can-fite-phase-2a-pancreatic-cancer-study-with-namodenoson</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.canfite.com/news-events/press-releases/detail/1116/can-fite-secures-japanese-patent-allowance-for</link>
                <pubDate>Fri, 26 Jun 26 07:00:00 -0400</pubDate>
                <guid>https://ir.canfite.com/news-events/press-releases/detail/1116/can-fite-secures-japanese-patent-allowance-for</guid>
                                                                            </item>
            </channel>
</rss>